Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026
Zenas BioPharma will present seven posters on orelabrutinib and obexelimab in multiple sclerosis at the 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026), October 21-23, 2026, in Toronto. The data include 24-week Phase 2 results for orelabrutinib and obexelimab in relapsing MS, plus designs of the Phase 3 Monarch (non-active SPMS) and PriMroSe (PPMS) trials of orelabrutinib. The company will also host an expert symposium on BTK inhibition in progressive MS.
Key figures
- Drug Name
- orelabrutinib; obexelimab
- Phase Of Trial
- Phase 2 (24-week data); Phase 3 trial designs (Monarch, PriMroSe)
- Conference
- MSToronto2026, October 21-23, 2026, Toronto
- Poster count
- 7
- Sunstone topline timing
- 4Q 2026
- Obexelimab trials to date
- 9 trials, 667 subjects
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.